Partnership Expanded Human Heart Cell Research
New human heart cells offer researchers a more precise tool for testing heart drug safety and efficacy.
Updated on Sept. 23, 2026 in Heart Disease
Live Poll
Should pharmaceutical research prioritize human cell models over animal testing to develop new drugs?
Bit.bio and Myriamed have launched a partnership to supply human iPSC-derived ventricular and atrial cardiomyocytes for drug discovery. This collaboration aims to improve how new medications are tested for safety before they reach clinical trials.
Why it matters
Drug-induced cardiotoxicity is a leading reason why potential heart medications fail, largely because traditional animal models often fail to replicate human heart biology. By using more accurate human cell models, researchers hope to identify toxic risks earlier in the development process.
The partnership integrates 10 years of cardiac specialization to provide cryopreserved human ventricular and atrial cardiomyocytes. While current methods for assessing cardiotoxicity remain prone to failure, these cells are designed for use in 3D tissue models and CRISPR screening.
The players
Bit.bio
A Cambridge-based biotechnology company focused on cell programming and the production of human cells for research and drug discovery.
Myriamed
A German biotechnology firm specializing in cardiac tissue modeling and the use of human cardiomyocytes for drug safety evaluation.
The details
The collaboration leverages cryopreserved induced pluripotent stem cell (iPSC)-derived cardiomyocytes that function in both 2D and 3D applications. These cells allow for the creation of human-based disease models, including those for dilated cardiomyopathy, and feature real-time reporters to monitor cardiac cell behavior. This approach provides a more physiologically relevant system for evaluating how drug compounds interact with human heart tissue at a cellular level.
Timeline
September 23, 2026: Bit.bio and Myriamed announced a partnership to provide specialized human cardiac cells.
Health Landscape
This partnership aligns with the scientific shift toward replacing unreliable animal models with human-derived cell systems for drug development. It marks a push to improve the accuracy of cardiac safety screenings in a landscape where drug attrition remains high due to cardiac toxicity.
While this development focuses on laboratory drug testing, it underscores the difficulty of predicting how individual patients react to heart medications. Patients should always discuss the potential for side effects and the rationale for specific cardiac treatments with their physician.
The takeaway
Reliable human heart cell models are critical to making new treatments safer for clinical use. Tracking updates on heart health innovation can help you have better conversations with your doctor about the risks and benefits of your current treatment plan.
Further reading
For more on the latest research in cardiac care and diagnostics, visit the Heart Disease section.
Source note: This article includes information reported by Scientist Live.
Live Poll
Should pharmaceutical research prioritize human cell models over animal testing to develop new drugs?
